New Treatment Options for CLL Patients from ibrutinib medication Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: In an exclusive interview, Dr. Tom Kipps, a CLL expert physician from the University of California in San Diego talks about new treatment options for CLL. Results from the Resonate Phase III study of Ibrutinib versus Ofatumumab in patients with relapsed or refractory Chronic Lymphocytic Leukemia was presented at the conference and the results were very positive for patients treated with Ibrutinib. Dr. Kipps goes on to explain that the study was a cross-over study so that patients could choose to
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)